Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code
x Close Forever Close
Volume 33 Issue 4
. 
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Pharmaceutical Practice and Service  > 2015  >  33(4): 303-308,379

ZENG Lingjun, KE Xiaowen, SONG Hongtao. Study on extraction technology of blood glucose-lowering components of total flavonoids and polysaccharides from Gynura divaricata (L.) DC.[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(6): 516-521. doi: 10.3969/j.issn.1006-0111.2016.06.009
Citation: JIANG Yan, SHENG Chunquan, DONG Guoqiang. Research progress of dual topoisomerase Ⅰ and Ⅱ inhibitors[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(4): 303-308,379. doi: 10.3969/j.issn.1006-0111.2015.04.004
shu

Research progress of dual topoisomerase Ⅰ and Ⅱ inhibitors

doi: 10.3969/j.issn.1006-0111.2015.04.004

  • Department of Medicinal Chemistry, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

  • Received Date: 2013-10-15
  • Rev Recd Date: 2014-02-19
  • DNA topoisomerases (Tops) are essential enzymes that regulate the cellular processes such as replication, transcription, recombination and repair. DNA Tops can be classified into two types, topoisomerase Ⅰ (TopⅠ) and topoisomerase Ⅱ (TopⅡ). They catalyze the breakage and religation of DNA, maintaining the topological changes of DNA and various DNA metabolic processes. Due to their important role in DNA metabolism, the ability to interfere with the functions of Tops or generating Top-mediated DNA damage is an effective strategy for cancer chemotherapy. Tops have been considered as the most important targets for tumor chemotherapy. In this review, we used examples to describe the development of dual topoisomerase Ⅰ and Ⅱ inhibitors.
  • [1] Wall ME, Wani MC, Cook CE, et al. Plant antitumor agents Ⅰ. The isolation and structure of camptothecin, a noveⅠ alkaloidal leukemia and tumor inhibitor from camptotheca acuminata1,2[J]. J Am Chem Soc, 1966, 88(16): 3888-3890.
    [2] Hsiang YH, Hertzberg R, Hecht S, et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase Ⅰ[J]. J Biol Chem, 1985, 260(27): 14873-14878.
    [3] Dallavalle S, Gattinoni S, Mazzini S, et al. Synthesis and cytotoxic activity of a new series of topoisomerase Ⅰ inhibitors[J]. Bioorg Med Chem Lett, 2008, 18(4): 1484-1489.
    [4] Kruczynski A, Barret JM, Van Hille B, et al. Decreased nucleotide excision repair activity and alterations of topoisomerase Ⅱ alpha are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases Ⅰ and Ⅱ[J]. Clin Cancer Res, 2004, 10(9): 3156(3168.
    [5] Kluza J, Mazinghien R, Irwin H, et al. Relationships between DNA strand breakage and apoptotic progression upon treatment of HL(60 leukemia cells with tafluposide or etoposide[J]. Anticancer Drugs, 2006, 17(2): 155(164.
    [6] Mucci(LoRusso P, Polin L, Bissery MC, et al. Activity of batracylin (NSC-320846) against solid tumors of mice[J]. Invest New Drugs, 1989, 7(4): 295-306.
    [7] Plowman J, Paull KD, Atassi G, et al. Preclinical antitumor activity of batracylin (NSC 320846)[J]. Invest New Drugs, 1988, 6(3): 147-153.
    [8] Rao VA, Agama K, Holbeck S, et al. Batracylin (NSC 320846), a dual inhibitor of DNA topoisomerases Ⅰ and Ⅱ induces histone gamma-H2AX as a biomarker of DNA damage[J]. Cancer Res, 2007, 67(20): 9971-9979.
    [9] Lewis LJ, Mistry P,Charlton PA,et al. Mode of action of the novel phenazine anticancer agents XR11576 and XR5944. Anticancer Drugs 2007, 18, 139-48.
    [10] de Jonge MJ, Kaye S, Verweij J, et al. Phase I and pharmacokinetic study of XR11576, an oral topoisomerase Ⅰ and Ⅱ inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours[J]. Br J Cancer, 2004, 91(8): 1459-1465.
    [11] Verborg W, Thomas H, Bissett D, et al. First-into-man phase Ⅰ and pharmacokinetic study of XR5944.14, a novel agent with a unique mechanism of action[J]. Br J Cancer, 2007, 97(7): 844-850.
    [12] Montaner B, Castillo-Avila W, Martinell M, et al. DNA interaction and dual topoisomerase Ⅰ and Ⅱ inhibition properties of the anti-tumor drug prodigiosin[J]. Toxicol Sci, 2005, 85(2): 870-879.
    [13] Montaner B, Navarro S, Pique M, et al. Prodigiosin from the supernatant of Serratia marcescens induces apoptosis in haematopoietic cancer cell lines[J]. Br J Pharmacol, 2000, 131(3): 585-593.
    [14] Montaner B, Perez-Tomas R. Prodigiosin-induced apoptosis in human colon cancer cells[J]. Life Sci, 2001, 68(17): 2025-2036.
    [15] Lin JK. Molecular targets of curcumin[J]. Adv Exp Med Biol, 2007, 595: 227-243.
    [16] Lopez-Lazaro M, Willmore E, Jobson A, et al. Curcumin induces high levels of topoisomerase Ⅰ-and Ⅱ-DNA complexes in K562 leukemia cells[J]. J Nat Prod, 2007, 70(12): 1884-1888.
    [17] Dhandapani KM, Mahesh VB,Brann DW. Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-Ⅰ and NF kappaB transcription factors[J]. J Neurochem, 2007, 102(2): 522-538.
    [18] Chih LL,Jen KL. Curcumin: a potential cancer chemopreventive agent through suppressing NF-κB signaling[J]. J Cancer Mol, 2008, 4(1): 11-16.
    [19] Choi JY, Seo CS, Zheng MS, et al. Topoisomerase Ⅰ and Ⅱ inhibitory constituents from the bark of Tilia amurensis[J]. Arch Pharm Res, 2008, 31(11): 1413-1418.
    [20] Ishiyama D, Kanai Y, Senda H, et al. Novel human topoisomerase Ⅰ inhibitors, topopyrones A, B, C and D. Ⅱ. Structure elucidation[J]. J Antibiot (Tokyo), 2000, 53(9): 873-878.
    [21] Kanai Y,Ishiyama D,Senda H,et al. Novel human topoisomerase Ⅰ inhibitors, topopyrones A, B, C and D. Ⅰ. Producing strain, fermentation, isolation, physico-chemical properties and biological activity. J Antibiot (Tokyo) 2000, 53, 863-72.
    [22] Khan QA, Elban MA; Hecht SM. The topopyrones poison human DNA topoisomerases Ⅰ and Ⅱ[J]. J Am Chem Soc, 2008, 130(39): 12888-12889.
    [23] Hecht SM, Khan QA, Maini R, et al. Topopyrones: Dual topoisomerase inhibitors. Patent PCT/US2009/050081, 2010.
    [24] López-Lázaro M, Willmore E,Austin CA. The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases Ⅰ and Ⅱ in cells[J]. Mutat Res, 2010, 696:41-47.
    [25] Demarquay D, Huchet M, Coulomb H, et al. BN80927: A novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo[J]. Cancer Res, 2004, 64:4942-4949.
    [26] Lavergne O, Demarquay D, Bailly C, et al. Topoisomerase Ⅰ-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins[J]. J Med Chem, 2000, 43(11): 2285-2289.
    [27] Taniguchi K, Kohno K, Kawanami K, et al. Drug-induced down-regulation of topoisomerase Ⅰ in human epidermoid cancer cells resistant to saintopin and camptothecins[J]. Cancer Res, 1996, 56(10): 2348-2354.
    [28] Basnet A, Thapa P, Karki R, et al. 2,4,6-Trisubstituted pyridines: synthesis, topoisomerase Ⅰ and Ⅱ inhibitory activity, cytotoxicity, and structure-activity relationship[J]. Bioorg Med Chem, 2007, 15(13): 4351-4359.
    [29] Dalla Via L, Magno SM, Gia O, et al. Benzothiopyranoindole-based antiproliferative agents: synthesis, cytotoxicity, nucleic acids interaction, and topoisomerases inhibition properties[J]. J Med Chem, 2009, 52(17): 5429-5441.
  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-032025-0400.250.50.7511.25Highcharts.com
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 83.7 %FULLTEXT: 83.7 %META: 14.4 %META: 14.4 %PDF: 1.9 %PDF: 1.9 %FULLTEXTMETAPDFHighcharts.com
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 25.0 %其他: 25.0 %其他: 0.5 %其他: 0.5 %China: 1.6 %China: 1.6 %Malaysia: 0.3 %Malaysia: 0.3 %United States: 0.2 %United States: 0.2 %[]: 0.3 %[]: 0.3 %三明: 0.2 %三明: 0.2 %上海: 1.9 %上海: 1.9 %东莞: 0.3 %东莞: 0.3 %中山: 0.2 %中山: 0.2 %临汾: 0.3 %临汾: 0.3 %丹东: 0.2 %丹东: 0.2 %北京: 8.5 %北京: 8.5 %南京: 0.3 %南京: 0.3 %台州: 0.2 %台州: 0.2 %合肥: 0.3 %合肥: 0.3 %天津: 0.2 %天津: 0.2 %宜春: 0.2 %宜春: 0.2 %广州: 0.5 %广州: 0.5 %张家口: 0.3 %张家口: 0.3 %成都: 0.6 %成都: 0.6 %拉贾斯坦邦: 0.3 %拉贾斯坦邦: 0.3 %揭阳: 0.2 %揭阳: 0.2 %晋中: 0.2 %晋中: 0.2 %杭州: 0.8 %杭州: 0.8 %枣庄: 0.2 %枣庄: 0.2 %武汉: 0.6 %武汉: 0.6 %泸州: 0.2 %泸州: 0.2 %洛阳: 0.2 %洛阳: 0.2 %温州: 0.2 %温州: 0.2 %潮州: 0.2 %潮州: 0.2 %盐城: 0.2 %盐城: 0.2 %石家庄: 0.3 %石家庄: 0.3 %福州: 0.2 %福州: 0.2 %秦皇岛: 0.2 %秦皇岛: 0.2 %芒廷维尤: 24.0 %芒廷维尤: 24.0 %芝加哥: 0.2 %芝加哥: 0.2 %苏州: 0.3 %苏州: 0.3 %衢州: 0.2 %衢州: 0.2 %西宁: 25.9 %西宁: 25.9 %许昌: 0.2 %许昌: 0.2 %赤峰: 0.2 %赤峰: 0.2 %运城: 0.8 %运城: 0.8 %郑州: 1.1 %郑州: 1.1 %长治: 0.3 %长治: 0.3 %黄冈: 1.0 %黄冈: 1.0 %黄冈市麻城: 0.2 %黄冈市麻城: 0.2 %龙岩: 0.2 %龙岩: 0.2 %其他其他ChinaMalaysiaUnited States[]三明上海东莞中山临汾丹东北京南京台州合肥天津宜春广州张家口成都拉贾斯坦邦揭阳晋中杭州枣庄武汉泸州洛阳温州潮州盐城石家庄福州秦皇岛芒廷维尤芝加哥苏州衢州西宁许昌赤峰运城郑州长治黄冈黄冈市麻城龙岩Highcharts.com
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Get Citation
PDF
XML

Article Metrics

Article views(5823) PDF downloads(932) Cited by()

Related
Proportional views

Research progress of dual topoisomerase Ⅰ and Ⅱ inhibitors

doi: 10.3969/j.issn.1006-0111.2015.04.004
  • Department of Medicinal Chemistry, School of Pharmacy, Second Military Medical University, Shanghai 200433, China
  • Received Date: 2013-10-15
  • Rev Recd Date: 2014-02-19

Abstract: DNA topoisomerases (Tops) are essential enzymes that regulate the cellular processes such as replication, transcription, recombination and repair. DNA Tops can be classified into two types, topoisomerase Ⅰ (TopⅠ) and topoisomerase Ⅱ (TopⅡ). They catalyze the breakage and religation of DNA, maintaining the topological changes of DNA and various DNA metabolic processes. Due to their important role in DNA metabolism, the ability to interfere with the functions of Tops or generating Top-mediated DNA damage is an effective strategy for cancer chemotherapy. Tops have been considered as the most important targets for tumor chemotherapy. In this review, we used examples to describe the development of dual topoisomerase Ⅰ and Ⅱ inhibitors.

ZENG Lingjun, KE Xiaowen, SONG Hongtao. Study on extraction technology of blood glucose-lowering components of total flavonoids and polysaccharides from Gynura divaricata (L.) DC.[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(6): 516-521. doi: 10.3969/j.issn.1006-0111.2016.06.009
Citation: JIANG Yan, SHENG Chunquan, DONG Guoqiang. Research progress of dual topoisomerase Ⅰ and Ⅱ inhibitors[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(4): 303-308,379. doi: 10.3969/j.issn.1006-0111.2015.04.004
shu

    HTML

Reference (29)

Catalog

  • HTML

版权所有：《药学实践与服务》编辑委员会

Supervisor & Sponsors: Address: No 325 Guohe Road, ShanghaiPost Code: 200433

Tel: （021）81871324,81871397 E-mail: yxsjzzs@163.com

网站备案号 沪ICP备05003363号-1

Supported by: Beijing Renhe Information Technology Co., Ltd.  

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return